FOXK2 and neoplasm: Furthermore, the 3-year OS rate indicated that patients with overexpressed FOXKs in their pre-neoadjuvant chemoradiotherapy (nCRT) tumor tissues had worse OS (56.9% in the FOXK1 group and 64.2% in the FOXK2 group, p < 0.01) than patients with low levels of FOXK1 and FOXK2 (93.1% and 87.0%, respectively, p < 0.01) in their pre-nCRT biopsies [35].